Ann-lii L. Cheng
No.57, Ln. 155, Sec. 3, Keelung Rd, 106
Da'an, TPQ, Taiwan
Da'an, TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 351 publications
Increased CCR5 expression in lymphoma cells and M2 macrophages is associated with poor prognosis in primary intestinal diffuse large B-cell lymphoma.
Journal: The journal of pathology. Clinical research
Published: April 11, 2026
Elevated phthalate exposure and metabolic susceptibility increased breast cancer risk: A 20-y follow-up study in Taiwan.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 09, 2026
Epigenetic reprogramming of hexokinase domain containing 1 (HKDC1) promotes proliferation in colorectal cancer.
Journal: American journal of cancer research
Published: January 10, 2026
Less Is More: A Single-Dose, Non-Waiting Neoadjuvant Immunotherapy Strategy for Hepatocellular Carcinoma.
Journal: Biomedical journal
Published: January 05, 2026
Less is more: A single-dose, non-waiting neoadjuvant immunotherapy strategy for hepatocellular carcinoma.
Journal: Biomedical journal
Published: January 05, 2026
Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial.
Journal: Liver cancer
Published: December 23, 2025
Expression of Poliovirus Receptor, the Ligand of TIGIT, Associated With Immune-Cold Tumor Microenvironment in Hepatocellular Carcinoma.
Journal: JCO precision oncology
Published: December 10, 2025
Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma.
Journal: Blood cancer journal
Published: December 09, 2025
Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib.
Journal: Liver cancer
Published: October 24, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.
Journal: Annals of hepatology
Published: October 03, 2025
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 24, 2025
Cabozantinib induces NLRP3-CASP1-GSDMD-dependent pyroptosis in hepatocellular carcinoma.
Journal: Life sciences
Published: August 20, 2025
Last Updated: 09/26/2026